Why the study?
The incidence and baseline predictors of LVEF returning to normal after DCM following standard anti-HF medication in postmenopausal women were not well defined.
What are the baseline predictors of LVEF returning to normal in postmenopausal women with dilated cardiomyopathy receiving standard anti-heart failure treatment?
What are the baseline predictors of LVEF returning to normal in postmenopausal women with dilated cardiomyopathy receiving standard anti-heart failure treatment?
Nearly half of postmenopausal women with dilated cardiomyopathy achieve LVEF recovery on standard therapy, which is predicted by higher systolic pressure, shorter HF duration, shorter QRS, smaller LVEDd, and higher baseline LVEF.
Supports risk stratification for LVEF recovery in postmenopausal dilated cardiomyopathy; hypothesis-generating and needs prospective confirmation.
OBJECTIVE: To analyse the incidence and baseline predictors of the left ventricular ejection fraction (LVEF) returning to normal after dilated cardiomyopathy (DCM) following intervention with standard anti-heart failure (HF) medication in postmenopausal women. METHODS: Data from consecutive postmenopausal women who were first diagnosed with DCM and received anti-HF treatment during 2011 to 2018 were prospectively retrieved. The study population was divided into the LVEF recovery (LVR) group and the LVEF unrecovered (LVU) group according to whether LVEF was > 50%. The primary endpoint was baseline predictors of LVEF returning to normal. RESULTS: LVEF returned to normal in 49.3% (210/426) of patients with DCM. LVEF was significantly higher in the LVR group than in the LVU group (57.4% ± 6.9% vs 44.2% ± 5.3%; hazard ratio 1.312, 95% confidence interval 1.015-1.726) at the final follow-up. High systolic pressure, a short history of HF, a short QRS interval, a small left ventricular end-diastolic diameter (LVEDd), and high LVEF at admission were independent predictors of LVEF returning to normal. CONCLUSIONS: LVEF returning to normal in postmenopausal women with DCM who receive standard anti-HF treatment is associated with systolic pressure, a history of HF, QRS interval, LVEDd, LVEF at admission, and favourable outcome.
No takes yet. Share an insight, caveat, or question.
Mao et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: